UNC Cancer Care at Nash

Rocky Mount, North Carolina 27804

1 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling